...
首页> 外文期刊>Circulation journal >Long-term treatment with san'o-shashin-to, a kampo medicine, markedly ameliorates cardiac ischemia-reperfusion injury in ovariectomized rats via the redox-dependent mechanism
【24h】

Long-term treatment with san'o-shashin-to, a kampo medicine, markedly ameliorates cardiac ischemia-reperfusion injury in ovariectomized rats via the redox-dependent mechanism

机译:桑普-shashin-to(一种坎波药物)的长期治疗通过氧化还原依赖性机制显着改善了去卵巢大鼠的心脏缺血再灌注损伤

获取原文
获取原文并翻译 | 示例

摘要

Background: Hormone replacement therapy has failed to reduce ischemic cardiovascular events in climacteric women. To explore alternative therapy, we examined whether san'o-shashin-to (TJ-113), a kampo medicine, ameliorates cardiac ischemia-reperfusion (IR) injury in a climacteric rat model. Methods and Results: Cardiac function and infarct size after IR were significantly exacerbated in ovariectomized rats as compared with sham-operated rats, whereas long-term treatment with a clinical dosage of TJ-113 for 4 weeks markedly improved these functional and morphological changes. Myocardial inducible nitric oxide synthase (iNOS) expression and peroxynitrite levels were significantly higher in ovariectomized rats compared with sham-operated rats, and long-term TJ-113 treatment significantly reduced these oxidative changes. Furthermore, myocardial manganese superoxide dismutase (Mn-SOD) activity was significantly lower in ovariectomized than in sham-operated rats, and long-term TJ-113 treatment significantly restored antioxidant activity. Importantly, those beneficial actions of TJ-113 were significantly inhibited by the estrogen receptor antagonist, fulvestrant, and the phytoestrogen, emodin, a TJ-113 ingredient, mimicked the actions of TJ-113, suggesting involvement of emodin in the effects of TJ-113. Conclusions: These results provide the first evidence that long-term treatment with a clinical dosage of TJ-113 markedly ameliorates cardiac IR injury in ovariectomized rats via inhibition of iNOS expression, suppression of peroxynitrite formation, and restoration of Mn-SOD activity. TJ-113 may be a novel therapeutic option in the treatment of ischemic heart disease in climacteric women. (Circ J 2013; 77: 1827-1837).
机译:背景:激素替代疗法未能减少更年期女性的缺血性心血管事件。为了探索替代疗法,我们检查了桑普沙辛-托(TJ-113)(一种坎普药物)是否能改善更年期大鼠模型的心脏缺血再灌注(IR)损伤。方法与结果:与假手术组相比,卵巢切除组大鼠的IR后心脏功能和梗死面积明显加重,而长期使用临床剂量TJ-113治疗4周可明显改善这些功能和形态学变化。与假手术大鼠相比,去卵巢大鼠的心肌诱导型一氧化氮合酶(iNOS)表达和过氧亚硝酸盐水平显着更高,长期TJ-113治疗可显着降低这些氧化变化。此外,去卵巢切除的大鼠心肌锰超氧化物歧化酶(Mn-SOD)活性明显低于假手术大鼠,长期TJ-113治疗可显着恢复抗氧化活性。重要的是,TJ-113的那些有益作用被雌激素受体拮抗剂富氟司特明显抑制,而植物雌激素大黄素(一种TJ-113成分)模仿了TJ-113的作用,表明大黄素参与了TJ-113的作用113。结论:这些结果提供了第一个证据,即长期使用临床剂量的TJ-113治疗可通过抑制iNOS的表达,抑制过氧亚硝酸盐的形成以及恢复Mn-SOD活性来明显改善卵巢切除大鼠的心脏IR损伤。 TJ-113可能是治疗更年期女性缺血性心脏病的一种新型治疗选择。 (Circ J 2013; 77:1827-1837)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号